Marinus Pharmaceuticals, Inc. (MRNS)
Feb 11, 2025 - MRNS was delisted (reason: acquired by Immedica)
0.5500
+0.0010 (0.09%)
Inactive · Last trade price
on Feb 11, 2025
Marinus Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Cash & Equivalents | 120.57 | 240.55 | 122.93 | 138.51 | 90.94 | Upgrade
|
| Short-Term Investments | 29.72 | - | - | 1.47 | 0.74 | Upgrade
|
| Cash & Short-Term Investments | 150.29 | 240.55 | 122.93 | 139.98 | 91.68 | Upgrade
|
| Cash Growth | -37.52% | 95.69% | -12.18% | 52.68% | 26.07% | Upgrade
|
| Receivables | 3.8 | 6.35 | 3.19 | 1.65 | - | Upgrade
|
| Inventory | 2.41 | 0.08 | - | - | - | Upgrade
|
| Prepaid Expenses | 8.75 | 5.4 | 5.57 | 4.64 | 2.45 | Upgrade
|
| Total Current Assets | 165.25 | 252.38 | 131.68 | 146.27 | 94.13 | Upgrade
|
| Property, Plant & Equipment | 4.84 | 5.54 | 4.2 | 3.95 | 4.47 | Upgrade
|
| Other Long-Term Assets | 0.82 | 1.6 | 0.96 | 0.25 | 0.24 | Upgrade
|
| Total Assets | 170.91 | 259.52 | 136.84 | 150.46 | 98.84 | Upgrade
|
| Accounts Payable | 4 | 4.46 | 3.13 | 2.21 | 2.76 | Upgrade
|
| Accrued Expenses | 22.09 | 16.45 | 15.65 | 8.01 | 4.82 | Upgrade
|
| Current Portion of Long-Term Debt | 13.76 | 1.02 | - | - | - | Upgrade
|
| Current Portion of Leases | 0.77 | 0.64 | 0.56 | 0.51 | 0.45 | Upgrade
|
| Current Income Taxes Payable | - | 2.45 | - | - | - | Upgrade
|
| Other Current Liabilities | - | - | 21.23 | - | - | Upgrade
|
| Total Current Liabilities | 40.62 | 25.02 | 40.57 | 10.73 | 8.03 | Upgrade
|
| Long-Term Debt | 95.19 | 100.88 | 40.81 | - | - | Upgrade
|
| Long-Term Leases | 0.63 | 1.34 | 1.98 | 2.53 | 3.04 | Upgrade
|
| Long-Term Unearned Revenue | 17.55 | 16.29 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 0.15 | - | - | - | - | Upgrade
|
| Total Liabilities | 154.14 | 143.52 | 83.35 | 13.26 | 11.07 | Upgrade
|
| Common Stock | 0.06 | 0.05 | 0.04 | 0.04 | 0.02 | Upgrade
|
| Additional Paid-In Capital | 588.66 | 542.43 | 459.85 | 444.62 | 295.12 | Upgrade
|
| Retained Earnings | -571.93 | -430.52 | -410.71 | -311.93 | -235.57 | Upgrade
|
| Comprehensive Income & Other | -0.02 | - | - | - | - | Upgrade
|
| Total Common Equity | 16.77 | 111.96 | 49.18 | 132.73 | 59.57 | Upgrade
|
| Shareholders' Equity | 16.77 | 116 | 53.49 | 137.2 | 87.77 | Upgrade
|
| Total Liabilities & Equity | 170.91 | 259.52 | 136.84 | 150.46 | 98.84 | Upgrade
|
| Total Debt | 110.36 | 103.87 | 43.34 | 3.04 | 3.49 | Upgrade
|
| Net Cash (Debt) | 39.93 | 136.68 | 79.58 | 136.94 | 88.19 | Upgrade
|
| Net Cash Growth | -70.79% | 71.74% | -41.88% | 55.27% | 21.27% | Upgrade
|
| Net Cash Per Share | 0.74 | 3.50 | 2.17 | 5.02 | 6.47 | Upgrade
|
| Filing Date Shares Outstanding | 54.64 | 49.67 | 37 | 36.58 | 21.68 | Upgrade
|
| Total Common Shares Outstanding | 54.58 | 49.64 | 36.79 | 36.58 | 21.62 | Upgrade
|
| Working Capital | 124.62 | 227.36 | 91.11 | 135.54 | 86.1 | Upgrade
|
| Book Value Per Share | 0.31 | 2.26 | 1.34 | 3.63 | 2.76 | Upgrade
|
| Tangible Book Value | 16.77 | 111.96 | 49.18 | 132.73 | 59.57 | Upgrade
|
| Tangible Book Value Per Share | 0.31 | 2.26 | 1.34 | 3.63 | 2.76 | Upgrade
|
| Machinery | 4.84 | 4.79 | 2.99 | 2.18 | 2.18 | Upgrade
|
| Leasehold Improvements | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.